MX2010006867A - Acidos grasos de longitud de cadena media, sales y trigliceridos en combinacion con gemcitabina para el tratamiento de cancer pancreatico. - Google Patents

Acidos grasos de longitud de cadena media, sales y trigliceridos en combinacion con gemcitabina para el tratamiento de cancer pancreatico.

Info

Publication number
MX2010006867A
MX2010006867A MX2010006867A MX2010006867A MX2010006867A MX 2010006867 A MX2010006867 A MX 2010006867A MX 2010006867 A MX2010006867 A MX 2010006867A MX 2010006867 A MX2010006867 A MX 2010006867A MX 2010006867 A MX2010006867 A MX 2010006867A
Authority
MX
Mexico
Prior art keywords
chain length
medium
gemcitabine
triglycerides
salts
Prior art date
Application number
MX2010006867A
Other languages
English (en)
Spanish (es)
Inventor
Lyne Gagnon
Lilianne Geerts
Christopher Penny
Original Assignee
Prometic Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biosciences Inc filed Critical Prometic Biosciences Inc
Publication of MX2010006867A publication Critical patent/MX2010006867A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2010006867A 2007-12-19 2008-12-18 Acidos grasos de longitud de cadena media, sales y trigliceridos en combinacion con gemcitabina para el tratamiento de cancer pancreatico. MX2010006867A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US812907P 2007-12-19 2007-12-19
PCT/CA2008/002190 WO2009076761A1 (en) 2007-12-19 2008-12-18 Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer

Publications (1)

Publication Number Publication Date
MX2010006867A true MX2010006867A (es) 2010-08-31

Family

ID=40795145

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006867A MX2010006867A (es) 2007-12-19 2008-12-18 Acidos grasos de longitud de cadena media, sales y trigliceridos en combinacion con gemcitabina para el tratamiento de cancer pancreatico.

Country Status (15)

Country Link
US (1) US8946190B2 (enExample)
EP (1) EP2231166B1 (enExample)
JP (1) JP5473937B2 (enExample)
KR (1) KR101603351B1 (enExample)
CN (1) CN101903028B (enExample)
AU (1) AU2008338204B2 (enExample)
BR (1) BRPI0821395A2 (enExample)
CA (1) CA2708679C (enExample)
DK (1) DK2231166T3 (enExample)
ES (1) ES2414617T3 (enExample)
MX (1) MX2010006867A (enExample)
NZ (1) NZ586249A (enExample)
PT (1) PT2231166E (enExample)
TW (1) TWI448290B (enExample)
WO (1) WO2009076761A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1015124B8 (pt) 2009-05-04 2021-05-25 Prometic Biosciences Inc compostos aromáticos substituídos para a prevenção ou tratamento de distúrbios sanguíneos; distúrbios renais, nefropatias e/ou complicações do distúrbio renal; doenças relacionadas com inflamação; e distúrbios relacionados ao estresse oxidativo, usos farmacêuticos dos mesmos e composição farmacêutica comprendendo ditos compostos
KR101821646B1 (ko) 2010-10-27 2018-01-25 프로메틱 파마 에스엠티 리미티드 암을 치료하기 위한 화합물 및 조성물
CN102617679B (zh) * 2012-03-13 2014-11-26 北京大学 一种共轭亚油酸与吉西他滨连接的前体药物制备方法及其应用
US9737538B2 (en) 2013-02-12 2017-08-22 Bend Research, Inc. Solid dispersions of low-water solubility actives
WO2014126969A1 (en) * 2013-02-12 2014-08-21 Bend Research, Inc. Solid dispersions of low-water solubility actives
MX377728B (es) * 2013-02-28 2025-03-11 Pronova Biopharma Norge As Composición que comprende un compuesto lípido, un triglicerido y un tensioactivo, y métodos de uso de la misma.
WO2015116782A1 (en) 2014-01-29 2015-08-06 Board Of Regents, The University Of Texas System Nucleobase analogue derivatives and their applications
CN120923343A (zh) 2018-10-11 2025-11-11 巴斯夫股份公司 芳族化合物及其医药用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990010441A1 (en) * 1989-03-13 1990-09-20 Thornfeldt Carl R Treatment of skin diseases and tumors
US6340705B1 (en) * 1999-09-10 2002-01-22 Monsanto Technology, Llc Use of α-linolenic acid metabolites for treatment or prevention of cancer
PT1385498E (pt) * 2001-04-18 2007-12-14 Prometic Biosciences Inc Ácidos gordos como factores de sobrevivência e activação de neutrófilos
EP1427366A2 (en) 2001-08-29 2004-06-16 UMD, Inc. Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
US20060012880A1 (en) * 2002-05-02 2006-01-19 Law Benjamin P Optical device with refractive and diffractive properties
WO2004069237A1 (en) 2003-02-07 2004-08-19 Prometic Biosciences Inc. Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis
ES2264886B1 (es) * 2005-05-12 2008-02-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales.

Also Published As

Publication number Publication date
CN101903028A (zh) 2010-12-01
NZ586249A (en) 2012-05-25
US20100273731A1 (en) 2010-10-28
AU2008338204B2 (en) 2015-03-05
PT2231166E (pt) 2013-06-17
WO2009076761A1 (en) 2009-06-25
EP2231166A1 (en) 2010-09-29
KR20100101134A (ko) 2010-09-16
CA2708679A1 (en) 2009-06-25
HK1151244A1 (en) 2012-01-27
CA2708679C (en) 2016-11-15
ES2414617T3 (es) 2013-07-22
AU2008338204A1 (en) 2009-06-25
CN101903028B (zh) 2013-06-05
KR101603351B1 (ko) 2016-03-14
BRPI0821395A2 (pt) 2015-06-16
TWI448290B (zh) 2014-08-11
TW200934494A (en) 2009-08-16
EP2231166A4 (en) 2012-02-22
EP2231166B1 (en) 2013-03-20
US8946190B2 (en) 2015-02-03
JP2011506492A (ja) 2011-03-03
JP5473937B2 (ja) 2014-04-16
DK2231166T3 (da) 2013-06-24

Similar Documents

Publication Publication Date Title
MX2010006867A (es) Acidos grasos de longitud de cadena media, sales y trigliceridos en combinacion con gemcitabina para el tratamiento de cancer pancreatico.
SG10201400685SA (en) Use Of Eicosapentaenoic Acid Ethyl Ester For Treating Hypertriglyceridemia
BR112014032905A2 (pt) métodos de redução do risco de um evento cardiovascular em um sujeito em terapia com estatina
AR075423A1 (es) Composicion farmaceutica que comprende un inhibidor de sglt-2, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y sus usos
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
SG10201908757TA (en) Boronic acids and esters as inhibitors of fatty amide hydrolase
NZ596228A (en) Compositions and methods for the treatment of inflammation
WO2015157559A3 (en) 10',11'-modified saxitoxins useful for the treatment of pain
TN2011000437A1 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
EA200900155A1 (ru) Модуляторы фармакокинетических свойств лекарственных средств
NO20092444L (no) Heteroarylamidderivater
BRPI1007877A2 (pt) "inibidores de dpp-iv para o tratamento de diabetes em pacientes pediátricos"
MX2009005413A (es) Formas cristalinas del acido zoledronico.
WO2008024433A3 (en) Haloalkyl-substituted pyrimidinone derivatives
WO2009004995A1 (ja) 生理活性物質を定着および発現させる方法
TW200505880A (en) Diarylcycloalkyl derivatives, process for their preparation and their use as pharmaceuticals
MX2007002689A (es) 7-azaindoles y su uso como agonistas de ppar.
TW200500349A (en) Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals
TNSN07068A1 (en) Substituted purinyl derivatives with immunomodulator and chemoprotective activity and use alone or with medium - chain length fatty acids or glycerides
BR112014002885A2 (pt) uso de composto orgânico para o tratamento da síndrome de noonan
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
GEP20125570B (en) Use of indazolemethoxyalkanoic acid for reducing levels of triglycerides, cholesterol and glucose
WO2009038090A1 (ja) セサミン類とアラキドン酸類を含有する組成物
GEP20125680B (en) Carbonic and sulphuric acid salts of 3-(2,2,2-trimethylhydra-zinium) ropionate esters and their use for 3-(2,2,2-rimethyl- hydrazinium) propionate dihydrate preparation
BR112012023063A2 (pt) processo para a preparação de uma composição para raio x, e, composição de diagnóstico para raio x

Legal Events

Date Code Title Description
FG Grant or registration